Business Context and Reporting Period
This Form 8-K filing by Prestige Brands Holdings, Inc. (now Prestige Consumer Healthcare Inc.) reports material events occurring on January 31, 2012. The primary events include the completion of a major acquisition of over-the-counter pharmaceutical brands from GlaxoSmithKline (GSK) and the execution of significant new debt financing to fund the transaction.
Key Financial Metrics and Capital Structure
- Acquisition Cost: $615 million in cash (subject to post-closing inventory adjustment) for 15 OTC brands.
- New Senior Notes: Issued $250 million aggregate principal amount of 8.125% Senior Notes due 2020.
- New Term Loan Facility: Established a $660 million seven-year term loan facility.
- New Revolving Credit Facility: Established a $50 million asset-based revolving credit facility (no amounts drawn at closing).
- Debt Servicing: Notes pay interest semiannually starting August 1, 2012. Term loan interest is based on LIBOR or Base Rate plus an initial margin of 4.00% or 3.00%, respectively, with a 1.5% original issue discount.
- Financial Covenants: The new credit facilities impose quarterly maximum total net leverage ratio and minimum consolidated cash interest coverage ratio tests.
Material Changes Versus Prior Period
The filing details a fundamental shift in the company's capital structure and asset base compared to the prior period:
- Asset Acquisition: Completed the purchase of 15 brands including BC, Goody's, Ecotrin, Beano, Gaviscon, Phazyme, Tagamet, Fiber Choice, and Sominex.
- Debt Refinancing: Terminated the 2010 Credit Agreement (Bank of America) with no material early termination penalties. Replaced it with the new senior secured credit facilities.
- Security Structure: Existing 8.25% Senior Notes due 2018 were secured equally and ratably with the new Term Loan Facility. The new Term Loan Facility holds a first lien on most assets, while the new ABL facility holds a first lien on accounts receivable and inventory.
Outlook, Risks, and Management Commentary
Management Commentary and Agreements:
- Supply Agreement: Entered a transitional manufacturing and supply agreement with GSK Healthcare for specific brands (e.g., Nytol, Tagamet, Beano) for periods of three to four years.
- Registration Rights: Committed to filing an exchange offer registration statement within 365 days to allow holders to exchange the new Notes for registered notes.
- Prepayment Obligations: Mandatory prepayments of the Term Loan are required using 100% of net cash proceeds from certain debt issuances and asset sales, and 50% of annual excess cash flow (starting fiscal year 2013).
Risks and Contingencies:
- Covenant Compliance: The company must adhere to restrictive covenants limiting additional debt, dividends, asset sales, and mergers.
- Events of Default: Includes nonpayment, breach of covenants, and change of control, which could trigger acceleration of debt.
- Pro Forma Data: Required pro forma financial information and financial statements of the acquired business are not included in this filing and will be submitted via amendment within 71 days.
Investor Verification Checklist
- Verify the final purchase price of the GSK assets after the post-closing inventory adjustment.
- Review the upcoming 10-K filing for the full text of the Indenture, Credit Agreements, and Intercreditor Agreement.
- Monitor the filing of the exchange offer registration statement for the 2020 Notes within the 365-day window.
- Assess the company's ability to meet the new quarterly leverage and interest coverage covenants given the increased debt load.
- Confirm the terms of the transitional supply agreement with GSK to ensure continuity of product manufacturing.